U.S. Mycoplasma Testing Market Size & Outlook, 2023-2030
U.S. mycoplasma testing market, 2018-2030 (US$M)
Related Markets
U.S. mycoplasma testing market highlights
- The U.S. mycoplasma testing market generated a revenue of USD 323.2 million in 2023 and is expected to reach USD 754.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
- In terms of segment, kits & reagents was the largest revenue generating product in 2023.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Mycoplasma testing market data book summary
| Market revenue in 2023 | USD 323.2 million |
| Market revenue in 2030 | USD 754.2 million |
| Growth rate | 12.9% (CAGR from 2023 to 2030) |
| Largest segment | Kits & reagents |
| Fastest growing segment | Services |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Kits & Reagents, Services |
| Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.2% of the global mycoplasma testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. mycoplasma testing market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 126.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Mycoplasma Testing Market Scope
Mycoplasma Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. mycoplasma testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 56.22% in 2023. Horizon Databook has segmented the U.S. mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. market for mycoplasma testing is expected to witness lucrative growth as it is the biggest market for biotechnology & biopharmaceuticals and a leader in biopharmaceutical R&D. According to data published by PhRMA in 2018, the U.S. biopharmaceutical industry invested around USD 102 billion in R&D activities.
Furthermore, the high prevalence of chronic diseases like cancer and extensive R&D activities by regional players for developing novel cell & gene therapies are expected to fuel the demand for cell culture solutions, which will likely drive the demand for mycoplasma testing over the forecast period. As per the American Cancer Society, in 2021, around 1.9 million new cases of cancer were estimated to be diagnosed in the U.S., with over 608,570 cancer-related deaths.
In addition, following the outbreak of COVID‐19, several U.S.-based companies were involved in extensive research for the development of novel vaccines & therapeutics, driving the demand for mycoplasma testing solutions for quality control applications.
Reasons to subscribe to U.S. mycoplasma testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. mycoplasma testing market databook
-
Our clientele includes a mix of mycoplasma testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. mycoplasma testing market size, by product, 2018-2030 (US$M)
U.S. Mycoplasma Testing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
